INO Shareholder Alert: April 7, 2026 Lead Plaintiff Deadline in Inovio Pharmaceuticals, Inc. Securities Class Action Lawsuit -- The Gross Law Firm

Core Viewpoint - Inovio Pharmaceuticals, Inc. is facing a securities class action lawsuit due to allegations of issuing materially false and misleading statements regarding its manufacturing processes and regulatory prospects for its lead product candidate, INO-3107 [2][4]. Group 1: Allegations and Class Period - The class period for the lawsuit is defined as October 10, 2023, to December 26, 2025 [2]. - Allegations include deficiencies in the manufacturing of Inovio's CELLECTRA device, which may prevent the company from submitting its lead product candidate, INO-3107, for FDA approval by the second half of 2024 [2]. - It is claimed that Inovio lacked sufficient information to justify INO-3107's eligibility for FDA accelerated approval or priority review, leading to overstated regulatory and commercial prospects [2]. Group 2: Next Steps for Shareholders - Shareholders who purchased shares during the class period are encouraged to register for the class action, with a deadline of April 7, 2026, to seek lead plaintiff status [3]. - Registered shareholders will be enrolled in a portfolio monitoring software to receive updates throughout the case lifecycle [3]. Group 3: Law Firm Information - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [4]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [4].